Diet–microbiome interactions: mechanisms, challenges, and personalized applications—a narrative review

Introduction The human gastrointestinal tract is colonized by a dense and diverse consortium of microorganisms—collectively termed the gut microbiota—that exert profound influence on host health. This symbiotic community contributes to essential physiological processes including nutrient metabolism, immune modulation, pathogen exclusion, and the preservation of intestinal barrier function. Among the myriad factors modulating microbial ecology, diet remains the most powerful and modifiable determinant, capable of rapidly reshaping microbiota composition and function with direct implications for host metabolic, inflammatory, and neurological outcomes.[1–3] Emerging research has underscored substantial inter-individual variability in microbial responses to identical dietary interventions, attributed to differences in microbial composition, gene content, and metabolic phenotypes.[4–6] This realization has catalyzed the field of personalized nutrition, which seeks to tailor dietary strategies to an individual’s microbiome, genomics, and clinical context. The integration of high-throughput sequencing, metagenomics, and multi-omics approaches has enabled the identification of microbial signatures predictive of diet-induced physiological changes.[7–9] Notably, evidence from studies such as the PREDICT trial illustrates that microbial profiling can outperform conventional dietary guidelines in predicting postprandial glycemic and lipid responses.[4] Furthermore, advances in metabolite profiling—particularly of short-chain fatty acids (SCFAs), bile acids, and neurotransmitter-like molecules—have elucidated key mechanistic pathways linking microbial activity with host health.[10,11] Nevertheless, the field faces pressing challenges, including methodological heterogeneity, the functional redundancy of microbial taxa, and data paucity in underrepresented populations.[12,13] The future of personalized nutrition will likely hinge on the development of artificial intelligence (AI)-assisted prediction models, real-time microbiome analytics, and precision-targeted interventions such as prebiotics and synbiotics.[14,15] Methodology This review was conducted as a narrative review aimed at synthesizing current knowledge on diet–microbiome interactions, mechanistic pathways, and their applications in personalized nutrition. Search strategy A literature search was carried out in PubMed, Scopus, and Web of Science databases covering the period January 2005 to August 2025. Search terms included combinations of keywords such as “diet,” “gut microbiome,” “metagenomics,” “short-chain fatty acids,” “personalized nutrition,” “AI-based nutrition,” “gut-brain axis,” and “microbiome clinical trials.” Boolean operators (AND/OR) were used to refine results. Reference lists of included studies were also screened to identify additional relevant articles. Inclusion criteria Original research articles (randomized controlled trials, cohort studies, case–control studies, and metagenomic investigations) reporting on diet–microbiome interactions. Studies involving human participants or relevant translational animal models. Articles focusing on mechanistic insights, metabolite profiling, AI-driven nutrition platforms, or clinical applications. Peer-reviewed articles published in English. Exclusion criteria Editorials, commentaries, and opinion pieces without primary data. Non-peer-reviewed sources, commercial promotional materials, and preprints lacking peer review. Studies not directly addressing diet–microbiome relationships. Literature synthesis framework The evidence was thematically organized into the following domains: Mechanistic pathways—focusing on microbial metabolites (eg, SCFAs, bile acids, neurotransmitters). Clinical and translational studies—including large-scale trials such as PREDICT and metagenomic cohort studies. Applications in personalized nutrition—emphasizing AI-driven prediction models and commercial platforms. Challenges and future directions—covering methodological heterogeneity, functional redundancy, causality, and ethical considerations. The synthesis prioritized critical appraisal of primary data, randomized trials, and metagenomic studies while using review articles only for conceptual framing. Diet–microbiome interactions and their impact on gut health The gut microbiome exhibits remarkable plasticity in response to dietary inputs. Diets enriched in fiber, complex carbohydrates, and polyphenols enhance microbial diversity and promote symbiotic taxa such as Faecalibacterium prausnitzii and Bifidobacterium spp., known for SCFA production and anti-inflammatory activity.[16] Polyphenols from plant-based sources act as prebiotics and antioxidants, sustaining microbial homeostasis.[16] Cheng and Zhang[16] demonstrated synergistic effects of fiber and polyphenols on microbial richness and host–microbe interaction pathways. Similarly, high-fiber bread enriched with defatted rice bran improved microbial alpha-diversity and gastrointestinal outcomes.[17] Conversely, Western diets rich in emulsifiers, preservatives, and saturated fats foster dysbiosis by suppressing beneficial microbes and promoting pro-inflammatory taxa. Schell and Chadaideh[18] reported that such dietary patterns increase systemic inflammation and cardiometabolic risks. Sanchis-Gomar et al[19] linked these diets with reduced SCFA production and adverse cardiovascular biomarkers. Plant-based diets demonstrate protective effects by supporting resilient microbial communities. Ng et al[20] reported significant increases in butyrate-producing bacteria and improved metabolic profiles following fiber-rich dietary interventions. Van and Galvao[21] highlighted Christensenella minuta as a microbe enriched by plant-based diets that promotes epithelial integrity and immune balance (Figure 1).Figure 1:: Comparative schematic illustrating microbiome changes in fiber-rich diets vs. Western diets, showing downstream health outcomes. SCFA, short-chain fatty acid.Mechanistic pathways Microbial metabolites act as pivotal intermediaries in translating dietary inputs into host physiological responses. Among these, short-chain fatty acids (SCFAs)—notably butyrate, propionate, and acetate—are central to maintaining gut and systemic health. SCFAs are primarily produced through the fermentation of dietary fibers by taxa such as Faecalibacterium prausnitzii, Roseburia spp., and Bifidobacterium spp. Butyrate serves as the main energy substrate for colonocytes, reinforcing epithelial barrier integrity, reducing intestinal permeability, and preventing translocation of pathogens and endotoxins into systemic circulation. Propionate influences hepatic gluconeogenesis and cholesterol metabolism, while acetate contributes to lipid biosynthesis and central appetite regulation. Collectively, SCFAs modulate insulin sensitivity, glucose homeostasis, and systemic inflammatory tone.[22] Pereira further emphasized the role of SCFAs in dampening pro-inflammatory signaling cascades, such as nuclear factor κB (NF-κB) activation, and in mitigating obesity-associated metabolic dysfunctions.[22] Beyond metabolic regulation, diet–microbiome interactions influence host gene expression via epigenetic modifications. SCFAs, especially butyrate, act as histone deacetylase (HDAC) inhibitors, promoting histone acetylation and thereby enhancing transcription of anti-inflammatory genes. Similarly, microbial metabolites can alter DNA methylation patterns, influencing genes implicated in immune function, metabolic pathways, and even the aging process. For instance, Khayatan et al[23] demonstrated that distinct gut microbiota profiles reshape host epigenomic landscapes, linking dietary inputs and microbial activity to systemic health trajectories. Other metabolite classes, including secondary bile acids and tryptophan-derived indoles, further extend microbiome-mediated regulation of host physiology. These metabolites interact with host nuclear receptors (eg, farnesoid X receptor [FXR], peroxisome proliferator-activated receptor gamma [PPARγ]) and immune signaling pathways, thereby influencing lipid metabolism, enterohepatic circulation, and neuro-immune communication. Taken together, the mechanistic evidence highlights a multi-layered framework in which diet shapes microbial communities, microbes generate bioactive metabolites, and these metabolites modulate host metabolism, immunity, and gene regulation. These processes provide a biological rationale for developing dietary interventions and personalized nutrition strategies that target microbial metabolic capacity to improve clinical outcomes (Figure 2).Figure 2:: Microbial metabolites as mediators of diet and host physiology. FXR, farnesoid X receptor; NF-κB, nuclear factor κB; PPARγ, peroxisome proliferator-activated receptor gamma.Challenges and knowledge gaps Despite rapid advances in microbiome science, significant barriers remain in translating these findings into clinically actionable strategies. One of the foremost challenges is the inter-individual variability in microbiota composition and function, which complicates the formulation of universal dietary recommendations. Individuals consuming the same diet may exhibit divergent metabolic and clinical outcomes depending on their baseline microbiome. Pereira[24] emphasized the urgent need for standardized methodologies in microbiome research, including consistent sequencing platforms, analytical pipelines, and reporting standards, to improve reproducibility and clinical relevance. Another critical limitation lies in the over-reliance on taxonomic profiles. Traditional 16S rRNA-based studies describe which organisms are present but fail to capture the true functional capacity of the microbiome. As a result, predictive accuracy regarding health outcomes is often limited. Integrating metabolomic and proteomic data can provide more meaningful insights into functional activity. For instance, deleterious metabolites such as trimethylamine N-oxide (TMAO)—implicated in cardiovascular disease—cannot be reliably inferred from microbial taxonomy alone. Litichevskiy et al[25] and Sabarathinam et al[26] demonstrated that only by combining multi-omics approaches could such metabolite-host interactions be identified and contextualized. Furthermore, establishing causality remains a formidable challenge. While many studies report correlations between diet, microbial taxa, and health outcomes, distinguishing whether these microbes actively drive disease processes or simply respond to dietary changes remains unresolved. Additionally, confounding factors such as genetics, lifestyle, antibiotic use, and cultural dietary practices further complicate interpretation and limit generalizability across diverse populations. These knowledge gaps underscore the necessity for multi-omics integration, harmonized frameworks, and well-powered longitudinal cohort studies that account for population diversity. Applications and personalized nutrition The convergence of next-generation sequencing, AI, and systems biology has catalyzed the development of precision nutrition platforms, marking a shift from generalized dietary guidelines to individualized interventions. These platforms integrate an individual’s gut microbiome composition, clinical phenotype, lifestyle patterns, and biochemical markers to design tailored dietary strategies aimed at improving metabolic health, glycemic regulation, immune modulation, and overall wellness.[27,28] The PREDICT studies, conducted by King’s College London and Harvard, provided landmark evidence for the feasibility of microbiome-guided nutrition. These large-scale trials demonstrated that personalized dietary interventions based on microbiome and host metabolic signatures significantly outperformed standardized diets in controlling postprandial glycemia and lipid responses.[4,26] Such findings validate the translational utility of microbiome profiling in clinical nutrition and support its integration into precision medicine paradigms. Commercial platforms have capitalized on these advances: Viome employs metatranscriptomic sequencing to capture microbial gene expression in real time, thereby reflecting dynamic functional changes rather than static taxonomic profiles. This allows for actionable dietary insights beyond species-level classification.[29] DayTwo uses machine learning algorithms trained on extensive microbiome–host interaction datasets to predict glycemic responses to specific foods, enhancing dietary adherence and metabolic control, particularly in individuals with diabetes.[30,31] Emerging applications extend beyond metabolic health into the gut–brain axis, where diet-induced microbial shifts are being investigated for their potential to influence mood, stress resilience, and cognitive performance. Platforms are exploring microbiome-centered approaches for managing neuroinflammatory conditions, anxiety, depression, and cognitive decline, representing a paradigm shift in behavioral health interventions.[4,32] Nevertheless, the translation of these platforms into mainstream practice raises ethical and regulatory considerations. Issues surrounding data ownership, algorithm transparency, commercial bias, and equitable access must be addressed to ensure that these innovations benefit diverse populations rather than exacerbating health disparities. Together, these applications highlight the transformative potential of microbiome-guided nutrition, while also emphasizing the importance of robust validation, ethical safeguards, and interdisciplinary collaboration to ensure responsible clinical integration (Table 1). Table 1 - Precision Nutrition Platforms. Platform/study Methodology Target outcomes Limitations PREDICT (King’s College London, Harvard) Large-scale cohort studies integrating gut microbiome profiling, clinical phenotype, and dietary interventions Improved prediction and management of postprandial glycemia and lipid metabolism compared to standardized diets Requires large, diverse cohorts; high inter-individual variability is still a challenge; needs long-term validation Viome Metatranscriptomic sequencing to capture real-time microbial gene expression and functional changes Actionable dietary insights beyond taxonomy, focusing on dynamic microbial activity and host metabolism Dependent on proprietary algorithms; limited independent validation; ethical/data ownership concerns DayTwo Machine learning algorithms trained on microbiome–host interaction data to predict glycemic responses Personalized dietary recommendations for diabetes management, glycemic control, and enhanced adherence Focuses mainly on glycemic outcomes; commercial model may restrict accessibility; requires broader validation Future directions The future of microbiome research lies in the integration of systems biology, multi-omics, and machine learning approaches to achieve a more comprehensive and predictive understanding of diet–microbiome interactions. Current single-layer analyses (eg, taxonomic sequencing alone) are insufficient to capture the dynamic complexity of host–microbe relationships. By combining metagenomics, metatranscriptomics, metabolomics, and proteomics, researchers can map not only “who is there but also “what they are doing and “how it influences host physiology.”[33] Such integrative approaches will refine our ability to predict individual dietary responsiveness, moving from descriptive associations to mechanistically grounded, causal models. Machine learning algorithms and AI-based platforms will play a pivotal role in processing high-dimensional datasets, uncovering hidden microbial signatures, and generating clinically actionable predictions in real time. Equity and inclusivity must also remain at the forefront. Most current studies disproportionately represent Western cohorts, limiting generalizability. Future research must incorporate ethnically and geographically diverse populations while accounting for culturally specific diets and lifestyle factors. This is especially important because dietary patterns, microbiome composition, and disease risk profiles vary widely across global populations. Addressing this gap will ensure that personalized nutrition is not limited to select demographics but becomes a globally relevant intervention. Additionally, longitudinal and interventional studies will be essential to establish causality, monitor the long-term sustainability of dietary effects, and assess clinical endpoints beyond metabolic markers, such as immune resilience, cognitive performance, and mental health. Collaborative frameworks that involve clinicians, data scientists, nutritionists, and policymakers will be necessary to translate these insights into scalable healthcare solutions. Finally, the ethical dimensions of microbiome-guided nutrition must be addressed. Data privacy, algorithm transparency, affordability, and equitable access are critical for ensuring that technological advances do not exacerbate health disparities. Conclusion The diet–microbiome axis represents one of the most promising frontiers in precision medicine. Diet not only shapes the composition and diversity of the gut microbiome but also drives the production of metabolites that regulate host metabolism, immunity, and even epigenetic programming. These insights provide a mechanistic basis for developing targeted nutritional interventions that can prevent, manage, and potentially reverse chronic diseases. As research progresses, the integration of multi-omics, AI-driven prediction models, and large-scale clinical validation will be pivotal in transforming microbiome science into personalized nutrition strategies with tangible health benefits. The incorporation of diverse global cohorts will further ensure the equity and cultural relevance of these approaches (Figure 3). In essence, the convergence of mechanistic insights, technological innovation, and ethical governance positions microbiome-guided nutrition to revolutionize healthcare. By moving beyond one-size-fits-all recommendations toward data-driven, individualized dietary strategies, we are on the cusp of a paradigm shift where nutrition becomes not just preventive, but personalized, predictive, and precise.Figure 3:: Flowchart showing interactions. AI, artificial intelligence; SCFA, short-chain fatty acids. NF-κB, nuclear factor κB.